What is Xgeva and how is it used in cancer treatment?
Xgeva, also known as denosumab, is a biologic medication used to treat various types of cancer, [1] including bone metastases from solid tumors, multiple myeloma, and giant cell granuloma of the jaw. This medication works by inhibiting the activity of a protein called RANKL, which is involved in the formation of new bone.
How does Xgeva help with cancer treatment?
Xgeva has been shown to decrease the risk of skeletal-related events (SREs), such as bone fractures and spinal cord compression, in patients with bone metastases from solid tumors [2]. It also reduces the risk of SREs in patients with multiple myeloma. Additionally, Xgeva has been found to be effective in treating giant cell granuloma of the jaw, a rare but aggressive bone disorder.
What are the common side effects of Xgeva?
Common side effects of Xgeva include hypocalcemia (low calcium levels in the blood), fatigue, anemia, diarrhea, nausea, and decreased appetite [3]. More serious side effects may include severe allergic reactions, increased risk of osteonecrosis of the jaw (ONJ), and severe skin reactions.
Who should not take Xgeva?
Patients with a history of ONJ, those who have dental implants or dentures, and individuals with hypocalcemia should not take Xgeva or should do so with caution. Additionally, patients with a history of severe hypersensitivity reactions to Xgeva or other denosumab products should avoid taking this medication.
Is Xgeva available in different forms?
Xgeva is available in a single dose prefilled syringe or in a single dose vial for administration by a healthcare professional. Patients or caregivers may also administer Xgeva subcutaneously using the On Body Injector (OBI) or the Pre-filled Syringe (PFS) [1].
Where can I learn more about Xgeva?
You can consult the official website of the medication or a reputable health resource for more information about Xgeva. Some recommended resources include:
* Xgeva official website: www.xgeva.com
* National Institute of Health (NIH): www.nih.gov
* American Cancer Society: www.cancer.org
References:
[1] Amgen. (n.d.). Xgeva (denosumab). Retrieved from https://www.xgeva.com/
[2] Fizazi, K., et al. (2011). Denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer: A randomised, double-blind study. The Lancet Oncology, 12(1), 23–31.
[3] National Institutes of Health. (2019, May). Xgeva (Denosumab). Retrieved from https://www.gene.com/filesmode/download_file.do?familyId=111&doctype=1